Seelos Therapeutics Buys Back Portion Of SLS002-Related Royalties

  • Seelos Therapeutics Inc (NASDAQ: SEEL) has amended the agreement with Vyera Pharmaceuticals AG, announced in March 2018, to develop SLS-002 to repurchase a significant portion of the royalties payable on any future net sales of SLS-002.
  • As additional consideration under the prior agreement, Seelos has agreed to pay a mid-teens percentage royalty on any future net sales of SLS-002. Under this amendment, for other cash payments, Seelos will repurchase 9% of the future royalties and reduce its royalty obligations to a mid-single-digit percentage on any future net sales of SLS-002.
  • Seelos has started dosing 90mg of SLS-002 in Part A of its Proof-of-Concept study in 16 patients who are imminently suicidal. Part A of the Proof-of-Concept study precedes Part B, which is a registrational double-blind placebo-controlled trial.
  • SLS-002 is intranasal racemic ketamine with two investigational new drug applications to treat acute suicidal ideation and behavior in major depressive disorder or post-traumatic stress disorder.
  • Price Action: SEEL gained 2.6% at $3.95 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsPenny StocksFDAGeneralroyalties
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!